MedTrace Logo

A Protocol of Irinotecan for Carcinoma of the Lung

NCT01654081 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-05-30

No results posted yet for this study

Summary

The goal of this trial is to demonstrate the potential clinical benefit of irinotecan chemotherapy in patients with a specific NSCLC phenotype, ISG15-positive. The use of irinotecan in subjects with ISG15-positive NSCLC will be associated with an improved rate of clinical benefit (objective response, disease stability, and time to progression) compared to historical controls that were not previously selected for ISG-15 expression.

Conditions

Interventions

DRUG

Irinotecan

Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle

Sponsors & Collaborators

  • Susanne Arnold

    lead OTHER

Principal Investigators

  • Susanne Arnold, M.D. · Lucille P. Markey Cancer Center at University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-05-31
Completion
2014-05-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01654081 on ClinicalTrials.gov